Drug Profile
Research programme: multi-specific antibodies - Amgen/GlaxoSmithKline
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator TeneoBio
- Developer Amgen; GSK
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 19 Oct 2021 TeneoBio has been acquired and merged into Amgen
- 22 Jan 2019 TESARO has been acquired and merged into GlaxoSmithKline